phase 2
-
Regulatory
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE)…
Read More » -
Spine
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company…
Read More » -
Biologics
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — —…
Read More » -
Biologics
BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
–Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— –15 Clinical Sites Identified, 12…
Read More » -
Biologics
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
—Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100– MELVILLE,…
Read More » -
Biologics
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
— First Site Will Enroll First Patient in the Clinical Study– MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies,…
Read More » -
Neuro
Remedy Pharmaceuticals Initiates Phase 2A Study of CIRARA™ in Spinal Cord Injury
NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA™, a breakthrough drug for treating acute…
Read More » -
Extremities
OrthoTrophix Completed Subject Enrollment of the Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis
OAKLAND, Calif., May 21, 2015 /PRNewswire/ — OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company completed subject…
Read More » -
Recon
TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee
ROCKVILLE, Md., May 11, 2015 /PRNewswire/ — TissueGene Inc. is pleased to announce that Dr. Moon Jong Noh, VP of Research…
Read More »